{"gene":"TMPRSS2","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":2020,"finding":"SARS-CoV-2 uses ACE2 as its entry receptor and TMPRSS2 for S protein priming; a clinically approved TMPRSS2 inhibitor (camostat mesylate) blocked viral entry into cells.","method":"Pseudovirus entry assay, authentic virus infection, pharmacological inhibition with camostat mesylate","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (pseudovirus, authentic virus, inhibitor blocking), widely replicated across many subsequent labs","pmids":["32142651"],"is_preprint":false},{"year":1999,"finding":"TMPRSS2 is a membrane-bound serine protease expressed on the cell surface; its expression in prostate epithelial cells is upregulated by androgens.","method":"cDNA microarray profiling, Northern analysis, in situ hybridization","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (microarray, Northern, ISH), foundational paper replicated by many subsequent studies","pmids":["10485450"],"is_preprint":false},{"year":2005,"finding":"TMPRSS2 undergoes recurrent chromosomal rearrangements with ETS transcription factor genes ERG and ETV1 in prostate cancer; the androgen-responsive promoter elements of TMPRSS2 drive overexpression of the fusion ETS family members.","method":"Bioinformatics outlier expression analysis, FISH, RT-PCR, cell line experiments","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — FISH and RT-PCR in 29 tumor samples, cell line mechanistic experiments, widely replicated","pmids":["16254181"],"is_preprint":false},{"year":2022,"finding":"Crystal structure of TMPRSS2 at 1.95 Å resolved in complex with the inhibitor nafamostat; TMPRSS2 is produced as a zymogen that undergoes autocatalytic maturation, cleaves SARS-CoV-2 spike protein at multiple sites including the S1/S2 site, and has a substrate-binding pocket with distinctive features that explain inhibitor specificity.","method":"Recombinant protein production, enzymatic activity assays, 1.95 Å X-ray co-crystal structure with nafamostat, IC50 measurements for clinical inhibitors","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure determination with functional validation (enzymatic assay, substrate cleavage, inhibitor ranking), single rigorous paper with multiple orthogonal methods","pmids":["35676539"],"is_preprint":false},{"year":2021,"finding":"TMPRSS2 expression level determines the entry pathway of SARS-CoV-2: in TMPRSS2-expressing cells, virus enters rapidly (~10 min) at the plasma membrane in a pH-independent manner; in cells lacking TMPRSS2, virus is endocytosed and enters via acid-activated cathepsin L (~40–60 min post-infection). The two pathways are mutually exclusive.","method":"Live-cell imaging of viral entry kinetics, pharmacological inhibition of TMPRSS2 vs. cathepsin L, TMPRSS2 overexpression in non-expressing cells","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal gain/loss-of-function, live imaging, pharmacological pathway dissection; multiple orthogonal methods in one study","pmids":["34159616"],"is_preprint":false},{"year":2022,"finding":"SARS-CoV-2 Omicron BA.1 spike is inefficiently cleaved at S1/S2 compared to Delta, and Omicron inefficiently uses TMPRSS2 for cell entry, shifting entry preference to the endocytic/cathepsin pathway; TMPRSS2 deletion affected Delta entry to a greater extent than Omicron, and syncytium formation by Omicron spike was substantially impaired consistent with defective TMPRSS2 usage.","method":"Pseudovirus entry assays, TMPRSS2 deletion experiments, drug inhibitor pathway studies, syncytium assays, spike cleavage analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (pseudovirus, authentic virus, TMPRSS2 KO, drug pathway inhibition, syncytium assay), published in Nature","pmids":["35104837"],"is_preprint":false},{"year":2020,"finding":"TMPRSS2 and TMPRSS4 facilitate SARS-CoV-2 spike fusogenic activity and promote viral entry into human small intestinal enterocytes; productive SARS-CoV-2 infection occurs in ACE2+ mature enterocytes in human small intestinal enteroids.","method":"Human small intestinal enteroid infection, spike fusogenicity assays, enterocyte infection experiments","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — primary human organoid model, spike fusogenicity assay, multiple tissue/cell-type validations in one study","pmids":["32404436"],"is_preprint":false},{"year":2021,"finding":"α1-antitrypsin (α1AT) binds and inactivates the serine protease TMPRSS2, thereby inhibiting SARS-CoV-2 spike-mediated entry and viral replication in cell lines and primary human airway epithelial cultures at physiological concentrations.","method":"Bronchoalveolar lavage peptide/protein library screen, TMPRSS2 enzymatic activity assay, viral replication assay in primary cells, binding assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — biochemical binding/inhibition assay plus functional viral infection assay in primary cells, multiple cell types tested","pmids":["33741941"],"is_preprint":false},{"year":2023,"finding":"TMPRSS2 functions as a proteinaceous receptor for the seasonal human coronavirus HKU1; TMPRSS2 binds the HKU1 receptor-binding domain with high affinity (Kd 334 and 137 nM for HKU1A and HKU1B), triggers HKU1 spike-mediated cell-cell fusion and pseudovirus infection; catalytically inactive TMPRSS2 mutants retain receptor function but cannot cleave HKU1 spike. Anti-TMPRSS2 nanobodies block HKU1 infection of primary human bronchial cells.","method":"Pseudovirus infection assays, cell-cell fusion assays, binding affinity measurements, catalytically inactive TMPRSS2 mutants, anti-TMPRSS2 nanobodies, authentic HKU1 virus infection of primary cells","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (Kd measurement, mutagenesis, pseudovirus, authentic virus, primary cells, nanobody neutralization), published in Nature","pmids":["37879362"],"is_preprint":false},{"year":2024,"finding":"Cryo-EM structure of HKU1 RBD bound to human TMPRSS2 reveals that HKU1 RBD recognizes TMPRSS2 via an insertion subdomain through three distinct interfaces; sialoglycan binding induces a conformational change in the NTD that promotes RBD opening for TMPRSS2 recognition, demonstrating a synergistic glycan/protein receptor mechanism. Positions 417 and 469 in TMPRSS2 are determinants of HKU1 host tropism.","method":"Cryo-EM structure determination, mutagenesis, binding assays, pseudovirus infection assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structure combined with mutagenesis and functional binding/infection assays in one study","pmids":["38964329"],"is_preprint":false},{"year":2024,"finding":"Crystal structure of HKU1-CoV RBD in complex with TMPRSS2 shows HKU1 recognizes residues lining the TMPRSS2 catalytic groove; structure of a receptor-blocking nanobody with zymogen and activated TMPRSS2 provides the structural basis of TMPRSS2 autocatalytic activating conformational change, which dramatically increases binding affinity for HKU1.","method":"X-ray crystal structure of HKU1 RBD/TMPRSS2 complex and nanobody/TMPRSS2 complexes, mutagenesis of interface residues, species comparison","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures of multiple complexes with mutagenesis validation, published in Cell","pmids":["38964326"],"is_preprint":false},{"year":2022,"finding":"TMPRSS2 is essential for SARS-CoV-2 Beta and Omicron infection in the murine airways; TMPRSS2 knockout mice showed strongly reduced replication of Beta variant in nose, trachea, and lung and were protected from weight loss and disease; Omicron infection was also significantly reduced in the upper and lower respiratory tract of TMPRSS2-KO mice despite Omicron preferring the cathepsin pathway in vitro.","method":"TMPRSS2-knockout mouse model, intranasal infection with Beta and Omicron variants, viral titer measurements in tissues, weight loss monitoring","journal":"Viruses","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean KO mouse model with defined in vivo phenotype, multiple variants tested, multiple tissue measurements","pmids":["36851486"],"is_preprint":false},{"year":2022,"finding":"Essential role of TMPRSS2 in SARS-CoV-2 infection of murine airways confirmed in vivo; Omicron replication is significantly reduced in TMPRSS2-knockout mice despite using the cathepsin pathway efficiently in vitro, demonstrating that in vivo TMPRSS2 dependency is not predicted by cell culture results alone.","method":"TMPRSS2-knockout mice, infection with multiple SARS-CoV-2 variants (Omicron, mouse-adapted QHmusX, Beta, Gamma), viral replication measurements in airways","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — TMPRSS2-KO mouse model, multiple viral strains, multiple tissue compartments, published in Nature Communications","pmids":["36243815"],"is_preprint":false},{"year":2022,"finding":"TMPRSS2 rs12329760 T allele (p.Val160Met substitution) reduces TMPRSS2 catalytic activity and is less able to support SARS-CoV-2 spike-mediated entry in vitro; the T allele is associated with reduced likelihood of severe COVID-19 in a large clinical cohort.","method":"HEK293 cell co-transfection with ACE2 and WT or V160M TMPRSS2, SARS-CoV-2 pseudovirus entry assay, logistic regression in 2,244 ICU patients (GenOMICC study)","journal":"Current research in translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro functional assay showing reduced catalytic activity plus large clinical association study, single lab for the in vitro work","pmids":["35104687"],"is_preprint":false},{"year":2021,"finding":"TMPRSS2 promotes SARS-CoV-2 evasion from NCOA7-mediated restriction: overexpression of TMPRSS2, which routes virus to plasma membrane fusion rather than endosomal entry, renders SARS-CoV-2 less sensitive to NCOA7-mediated restriction; removal of the furin cleavage site similarly reduced NCOA7 sensitivity.","method":"TMPRSS2 overexpression, NCOA7 ectopic expression and gene knockout, spike pseudovirus infection, furin cleavage site mutagenesis","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function and loss-of-function with mechanistic mutagenesis, single lab","pmids":["34807954"],"is_preprint":false},{"year":2021,"finding":"Hydroxychloroquine blocks SARS-CoV-2 entry mediated by cathepsin L but not by TMPRSS2; SARS-CoV-2 entry is more dependent on TMPRSS2 than SARS-CoV-1 entry, a difference reversed by ablating the SARS-CoV-2 furin-cleavage site or introducing it into the SARS-CoV-1 spike.","method":"Pseudovirus entry assays with cathepsin vs. TMPRSS2 pathway inhibitors, spike furin-site mutagenesis, combination drug treatment experiments","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro reconstitution-like assay with mutagenesis demonstrating mechanistic basis, multiple orthogonal pharmacological and genetic approaches","pmids":["33465165"],"is_preprint":false},{"year":2017,"finding":"Wild-type clinical isolates of human coronaviruses HCoV-OC43 and HCoV-HKU1 prefer cell-surface TMPRSS2 over endosomal cathepsins for cell entry in human airway epithelial cells; cell-culture-adapted HCoV-OC43 lost the ability to infect air-liquid interface cultures of human bronchial tracheal epithelial cells.","method":"Viral infection assays with cell-surface vs. endosomal pathway inhibitors, comparison of clinical isolates vs. cell-culture-adapted strains, air-liquid interface culture infection","journal":"Virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway dissection in physiologically relevant primary airway cultures, multiple coronavirus strains tested, single lab","pmids":["29217279"],"is_preprint":false},{"year":2022,"finding":"Furin and TMPRSS2 act synergistically in SARS-CoV-2 S protein processing and viral entry: furin primes S at S1/S2, and TMPRSS2-mediated ACE2 shedding is required for TMPRSS2-mediated enhancement of cell-to-cell fusion in the absence of S1/S2 priming; the collectrin dimerization domain of ACE2 is essential for the TMPRSS2 effect on fusion; the S2' cleavage site was identified as KPS815↓ and is strongly enhanced by ACE2 engagement.","method":"Proteomics identification of S2' cleavage site, pharmacological furin inhibitors (BOS), camostat (TMPRSS2 inhibitor), quantitative cell-to-cell fusion assays, ACE2 domain deletion experiments, SARS-CoV-2 infection of Calu-3 cells","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — proteomics-level cleavage site identification, mutagenesis/domain deletions, quantitative fusion assays, pharmacological combination treatment, multiple orthogonal approaches","pmids":["35343766"],"is_preprint":false},{"year":2022,"finding":"The small-molecule TMPRSS2 inhibitor N-0385 exhibits low nanomolar potency against SARS-CoV-2 in human lung cells and colonoids; in K18-hACE2 transgenic mice, N-0385 provides high-level prophylactic and therapeutic benefit after multiple or single administrations, demonstrating that TTSP-mediated proteolytic maturation of spike is critical for SARS-CoV-2 infection in vivo.","method":"In vitro potency assays in Calu-3 and colonoids, K18-hACE2 transgenic mouse model, prophylactic and therapeutic dosing regimens, multiple variant testing","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo transgenic mouse model with prophylactic and therapeutic paradigms, multiple variants, multiple cell types in vitro, published in Nature","pmids":["35344983"],"is_preprint":false},{"year":2020,"finding":"HAI-2 (hepatocyte growth factor activator inhibitor-2) is a cognate inhibitor of TMPRSS2: HAI-2 binds TMPRSS2 with high affinity, co-localizes with TMPRSS2, inhibits TMPRSS2 proteolytic activity through both KD1 and KD2 domains, suppresses TMPRSS2-induced pro-HGF activation and extracellular matrix degradation, and blocks TMPRSS2-induced prostate cancer metastasis in orthotopic xenograft mice.","method":"Co-immunoprecipitation with LC/MS/MS identification, recombinant protein inhibitory assays, immunofluorescence co-localization, pro-HGF activation assay, invasion assay, orthotopic xenograft mouse model","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP plus biochemical inhibition assay plus in vivo xenograft confirmation, multiple orthogonal methods in one study","pmids":["32778768"],"is_preprint":false},{"year":2020,"finding":"DNA damage induces proteasomal degradation of TMPRSS2-ERG oncoprotein through ERG Thr-187 and Tyr-190 phosphorylation by GSK3β and WEE1 kinases respectively; dual phosphorylation triggers recognition and ubiquitin-mediated degradation by the E3 ligase FBW7 independent of a canonical degron. PTEN deletion or GSK3β inactivation abolishes this degradation.","method":"Phosphorylation site mutagenesis, kinase knockdown/inhibition (GSK3β, WEE1), co-immunoprecipitation with FBW7, proteasome inhibitor experiments, in vitro cell culture and mouse xenograft chemotherapy resistance experiments","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — active-site mutagenesis, kinase identification, E3 ligase co-IP, in vivo xenograft validation, multiple orthogonal methods","pmids":["32871104"],"is_preprint":false},{"year":2019,"finding":"AR/FOXA1 binding to enhancers E1 and E2 on chromosome 21 mediates chromatin looping that co-regulates both TMPRSS2 and PRCAT38; acetyltransferase p300 activity mediates loop formation and enhancer activity; knockout of either enhancer simultaneously impaired transcription of both genes and inhibited cell growth and migration.","method":"ChIP-seq, chromatin conformation capture (looping assays), CRISPR enhancer knockout, qRT-PCR, cell proliferation and migration assays","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR enhancer KO, ChIP, looping assays; single lab with multiple orthogonal methods","pmids":["31405024"],"is_preprint":false},{"year":2021,"finding":"IL-1β promotes TMPRSS2 expression and SARS-CoV-2 cell entry through the p38 MAPK–GATA2 signaling axis in lung epithelial cells.","method":"Cytokine treatment of cells, p38 MAPK inhibitors, GATA2 manipulation, TMPRSS2 expression measurement, pseudovirus/viral infection assays","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway dissection with pharmacological inhibitors and transcription factor manipulation, single lab","pmids":["34950146"],"is_preprint":false},{"year":2022,"finding":"An RNA G-quadruplex (RG4) structure within the TMPRSS2 mRNA inhibits TMPRSS2 translation; G4-stabilizing compounds attenuate SARS-CoV-2 infection in pseudovirus cell systems and mouse models; TMPRSS2 protein is increased in lungs of COVID-19 patients, consistent with loss of RG4-mediated translational repression.","method":"Bioinformatics RG4 prediction, biochemical/biophysical RG4 assays, translation reporter assays, G4 stabilizer treatment, pseudovirus infection, mouse infection model, COVID-19 patient lung protein analysis","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical RG4 validation, functional translation assay, in vivo mouse model; single lab","pmids":["35301316"],"is_preprint":false},{"year":2023,"finding":"PM2.5 activates AhR which translocates to the nucleus, binds the TMPRSS2 promoter, and upregulates TMPRSS2 and IL-18 expression to promote lung cancer progression; TMPRSS2 depletion in lung cancer cells suppressed anchorage-independent growth and xenograft tumor growth in mice.","method":"AhR nuclear translocation and ChIP at TMPRSS2 promoter, siRNA/shRNA TMPRSS2 knockdown, xenograft mouse model, anchorage-independent growth assay, PM2.5 long-term exposure cell model","journal":"EMBO molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-based promoter binding, KO functional assay with in vivo xenograft, single lab","pmids":["36975376"],"is_preprint":false},{"year":2022,"finding":"Antithrombin (AT) binds and inhibits TMPRSS2 as shown by molecular docking and enzyme activity assays; AT blocks entry of SARS-CoV, MERS-CoV, hCoV-229E, SARS-CoV-2 and Omicron spike-driven entry; activation of AT by heparin or fondaparinux increases its anti-TMPRSS2 activity.","method":"Molecular docking, TMPRSS2 enzymatic activity assays, spike pseudovirus entry assays, authentic SARS-CoV-2 lung cell infection, anticoagulant activation experiments","journal":"Journal of medical virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — enzymatic inhibition assay plus pseudovirus and authentic virus experiments, single lab","pmids":["36056630"],"is_preprint":false},{"year":2022,"finding":"Lactoferricin and the N-terminal lactoferrin peptide pLF1 inhibit TMPRSS2 proteolytic activity, block SARS-CoV-2 spike protein processing, and inhibit SARS-CoV-2 infection of permissive cells.","method":"TMPRSS2 enzymatic activity assay, spike cleavage assay, SARS-CoV-2 pseudovirus and authentic virus infection assays","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — enzymatic inhibition plus viral infection functional assays, single lab","pmids":["36081512"],"is_preprint":false},{"year":2022,"finding":"Peptidomimetic compounds designed to target the TMPRSS2 catalytic site inhibit TMPRSS2 serine protease activity, block SARS-CoV-2 spike pseudovirus entry, and inhibit authentic SARS-CoV-2 infection (including Delta and Omicron BA.1) with comparable efficacy to camostat mesylate; inhibitors are stable in blood serum/plasma.","method":"Molecular docking, TMPRSS2 enzymatic inhibition assays, SARS-CoV-2 pseudovirus entry assays, authentic SARS-CoV-2 infection assays, serum/plasma stability assays","journal":"Communications biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — structure-guided design with biochemical and multiple viral functional assays, single lab","pmids":["35804152"],"is_preprint":false},{"year":2001,"finding":"TMPRSS2 is expressed in the epithelia of gastrointestinal, urogenital, and respiratory tracts in mice; in both mouse and human prostate, expression is localized to luminal epithelial cells. Mouse TMPRSS2 predicted protein shares 81.4% similarity with human TMPRSS2.","method":"Mouse TMPRSS2 cDNA cloning, Northern blot, in situ hybridization of mouse embryos and adult tissues, comparative expression analysis","journal":"The Journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods (Northern, ISH, cDNA cloning) in mouse and human tissues, single lab","pmids":["11169526"],"is_preprint":false},{"year":2011,"finding":"TMPRSS2-ERG fusion product (but not wild-type ERG) negatively regulates PSMA expression at the transcriptional level; androgen stimulation increases TMPRSS2-ERG expression in VCaP cells, leading to decreased PSMA mRNA; ERG siRNA knockdown in VCaP cells enhances PSMA expression; TMPRSS2-ERG overexpression in LNCaP cells downregulates PSMA in a PSMA-luciferase reporter assay.","method":"siRNA knockdown of ERG, TMPRSS2-ERG overexpression in LNCaP cells, PSMA luciferase reporter assay, androgen treatment, flutamide (androgen antagonist) treatment","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with reporter assay, single lab with multiple orthogonal approaches","pmids":["21731703"],"is_preprint":false},{"year":2019,"finding":"TMPRSS2-ERG fusion protein directly and specifically regulates expression of the α1 and β1 subunits of soluble guanylyl cyclase (sGC), activating NO-cGMP-PKG signaling; ERG increases cGMP synthesis and PKG activity in prostate cancer cells; sGC inhibitor treatment represses tumor growth in TMPRSS2-ERG-positive PCa xenograft models and synergizes with enzalutamide.","method":"ChIP-seq, gene expression profiling, cGMP assay, PKG activity assay, sGC inhibitor treatment in xenograft models, ERG knockdown","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq, biochemical signaling assays, in vivo xenograft, single lab","pmids":["30718921"],"is_preprint":false},{"year":2018,"finding":"TMPRSS2-ERG fusion product mediates prostate oncogenesis by binding to BAF (mammalian SWI/SNF) ATP-dependent chromatin remodeling complexes; ERG drives genome-wide retargeting of BAF complexes in an ETS DNA-motif-dependent manner; ERG requires intact BAF complexes for chromatin occupancy and BAF ATPase activity for target gene regulation; in prostate organoids, BAF complexes are required for ERG-mediated basal-to-luminal transition.","method":"Co-immunoprecipitation, ChIP-seq for ERG and BAF subunits, BAF inhibition/depletion, prostate organoid model, gene expression profiling","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP, genome-wide ChIP-seq, organoid functional model, ATPase activity requirement; multiple orthogonal methods, published in Molecular Cell","pmids":["30078722"],"is_preprint":false},{"year":2017,"finding":"FOXO1 binds and inhibits the transcriptional activity of prostate cancer-associated ERG (including TMPRSS2-ERG fusion product) independently of FOXO1's own transcriptional activity; knockdown of endogenous FOXO1 increases invasion of TMPRSS2-ERG fusion-positive VCaP cells, an effect abolished by ERG knockdown; combined ERG transgene expression and Foxo1 deletion in mice results in high-grade prostatic intraepithelial neoplasia.","method":"Co-immunoprecipitation, ERG luciferase reporter assay, siRNA knockdown (FOXO1, ERG), invasion assay, transgenic/Foxo1-knockout mouse prostate model","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, reporter assay, in vivo mouse epistasis model; multiple orthogonal methods, single lab","pmids":["28986382"],"is_preprint":false},{"year":2014,"finding":"TMPRSS2-ERG fusion drives prostate cell proliferation and blocks differentiation to both neuroendocrine (NE) and luminal cell types; ERG represses AR-independent neuronal/NE genes and AR-regulated luminal genes; NE cells generated upon ERG knockdown/AR-inhibition are resistant to pharmacological AR inhibition and can revert to parental phenotype upon AR/ERG signaling restoration.","method":"ERG knockdown in TMPRSS2-ERG-positive cell line, ERG transgenic mouse model, transcriptional profiling, cell sorting, proliferation assays, androgen signaling inhibition","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockdown and transgenic mouse with transcriptional profiling and cell fate assays, single lab","pmids":["25263440"],"is_preprint":false},{"year":2018,"finding":"BRD4 is essential for repair of DNA double-strand breaks and mediates formation of TMPRSS2-ERG gene rearrangements through the non-homologous end joining (NHEJ) pathway; genome-wide DNA breaks are associated with enhanced H4 acetylation leading to BRD4 recruitment and establishment of the DNA repair complex.","method":"BETi pharmacological inhibition, genome-wide DNA break mapping, ChIP for BRD4 and histone acetylation marks, NHEJ functional assays, clinical sample BRD4 protein analysis","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, genome-wide DSB mapping, BETi functional experiments; single lab with multiple methods","pmids":["29346775"],"is_preprint":false},{"year":2022,"finding":"TMPRSS2 is identified as a receptor for Paeniclostridium sordellii hemorrhagic toxin (TcsH) via genome-wide CRISPR/Cas9 screens; genetic deletion of TMPRSS2 confers cellular resistance to TcsH intoxication; TMPRSS2 and fucosylated glycans act as independent/redundant receptors both binding TcsH through its CROPs domain; Tmprss2-/- mice are protected from TcsH-induced systemic toxicity and colonic epithelial lesions.","method":"Genome-wide CRISPR/Cas9 screen (two parallel screens), TMPRSS2 genetic deletion, binding assays with CROPs domain, Tmprss2-/- mouse model","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide CRISPR screen validated by KO, domain binding assay, in vivo KO mouse model, published in Nature Communications","pmids":["35882856"],"is_preprint":false}],"current_model":"TMPRSS2 is a type II transmembrane serine protease that undergoes autocatalytic zymogen activation; it primes the spike proteins of SARS-CoV-2 (at S1/S2 and S2' sites), other coronaviruses (including SARS-CoV, MERS-CoV, HCoV-229E, OC43, and HKU1), and influenza viruses by proteolytic cleavage, enabling virus-host membrane fusion at the plasma membrane surface (bypassing the endosomal cathepsin pathway); for HKU1, TMPRSS2 additionally serves as a direct proteinaceous receptor recognized by the RBD; in the prostate, TMPRSS2 expression is androgen-regulated via AR/FOXA1-driven enhancers, and its promoter region drives recurrent fusion with ETS oncogenes (most commonly ERG) in ~50% of prostate cancers, with the fusion product activating BAF chromatin remodeling, NO-cGMP signaling, and blocking neuroendocrine/luminal differentiation; its cognate endogenous inhibitor is HAI-2, and it is also inhibited by circulating serpins α1-antitrypsin and antithrombin; TMPRSS2-ERG oncoprotein is degraded by the proteasome following GSK3β/WEE1-mediated dual phosphorylation and FBW7 recognition."},"narrative":{"mechanistic_narrative":"TMPRSS2 is an androgen-regulated, cell-surface type II transmembrane serine protease that is produced as a zymogen and undergoes autocatalytic maturation, with its substrate-binding pocket explaining the specificity of clinical inhibitors [PMID:10485450, PMID:35676539]. Its best-characterized role is in respiratory and enteric virus entry: TMPRSS2 primes the spike protein of SARS-CoV-2 by cleaving at the S1/S2 and S2' (KPS815↓) sites, enabling rapid, pH-independent fusion at the plasma membrane and bypassing the slower endosomal cathepsin L pathway, with the two entry routes being mutually exclusive [PMID:32142651, PMID:34159616, PMID:35343766]. This priming function extends across coronaviruses (HCoV-OC43, HKU1) and is required in vivo, as TMPRSS2-knockout mice show strongly reduced replication of multiple SARS-CoV-2 variants even when those variants favor the cathepsin pathway in culture [PMID:36851486, PMID:36243815, PMID:29217279, PMID:35344983]. For HKU1, TMPRSS2 additionally serves as a direct proteinaceous receptor: the HKU1 receptor-binding domain engages the TMPRSS2 catalytic groove through an insertion subdomain, sialoglycan binding promotes RBD opening, and autocatalytic activation increases receptor affinity, while catalytically dead TMPRSS2 still functions as a receptor [PMID:37879362, PMID:38964329, PMID:38964326]. TMPRSS2 is inhibited by the cognate inhibitor HAI-2 and by circulating serpins α1-antitrypsin and antithrombin, all of which block its proteolytic activity and viral entry [PMID:33741941, PMID:32778768, PMID:36056630]. Independently, the androgen-responsive TMPRSS2 promoter drives recurrent fusion with ETS oncogenes (ERG, ETV1) in prostate cancer; the TMPRSS2-ERG oncoprotein retargets BAF (SWI/SNF) chromatin-remodeling complexes, activates NO-cGMP-PKG signaling, blocks neuroendocrine and luminal differentiation, and is destabilized by GSK3β/WEE1-driven dual phosphorylation and FBW7-mediated proteasomal degradation [PMID:16254181, PMID:32871104, PMID:30078722, PMID:30718921, PMID:25263440]. TMPRSS2 is also a receptor for Paeniclostridium sordellii hemorrhagic toxin TcsH [PMID:35882856].","teleology":[{"year":1999,"claim":"Established TMPRSS2 as a cell-surface serine protease whose expression is androgen-driven in prostate epithelium, defining the regulatory wiring later exploited by oncogenic fusions.","evidence":"cDNA microarray, Northern blot, and in situ hybridization in prostate epithelial cells","pmids":["10485450"],"confidence":"High","gaps":["Did not identify physiological substrates","No mechanism for how androgen signaling reaches the gene"]},{"year":2001,"claim":"Mapped TMPRSS2 tissue distribution to GI, urogenital, and respiratory epithelia and to prostate luminal cells, establishing the anatomical contexts relevant to both cancer and later viral entry roles.","evidence":"cDNA cloning, Northern blot, in situ hybridization in mouse and human tissues","pmids":["11169526"],"confidence":"Medium","gaps":["Functional consequence of broad epithelial expression unaddressed","No protease activity data"]},{"year":2005,"claim":"Showed that the androgen-responsive TMPRSS2 promoter fuses to ETS oncogenes (ERG, ETV1) to drive their overexpression, defining the founding oncogenic mechanism of TMPRSS2 in prostate cancer.","evidence":"Outlier expression bioinformatics, FISH, RT-PCR, and cell line experiments in prostate tumors","pmids":["16254181"],"confidence":"High","gaps":["Did not establish downstream effector pathways of the fusion oncoprotein","Mechanism of rearrangement formation unknown"]},{"year":2017,"claim":"Demonstrated that clinical coronavirus isolates prefer cell-surface TMPRSS2 over endosomal cathepsins, foreshadowing TMPRSS2 as a general coronavirus entry factor.","evidence":"Pathway-inhibitor infection assays comparing clinical vs. culture-adapted strains in human airway cultures","pmids":["29217279"],"confidence":"Medium","gaps":["Direct cleavage of spike not biochemically resolved here","Single-lab pharmacological dissection"]},{"year":2018,"claim":"Resolved how the TMPRSS2-ERG oncoprotein reprograms chromatin and cell fate, showing it retargets BAF complexes and blocks differentiation, explaining its oncogenic output.","evidence":"Co-IP, ERG/BAF ChIP-seq, BAF depletion, and prostate organoid basal-to-luminal transition assays; plus ERG-driven repression of NE/luminal programs","pmids":["30078722","25263440"],"confidence":"High","gaps":["How fusion alters BAF assembly stoichiometry unresolved","Relationship between chromatin retargeting and clinical progression incomplete"]},{"year":2019,"claim":"Identified the AR/FOXA1-driven enhancers and downstream NO-cGMP-PKG signaling axis activated by TMPRSS2-ERG, linking enhancer biology to a druggable oncogenic effector pathway.","evidence":"ChIP-seq, chromatin looping, CRISPR enhancer knockout; sGC subunit ChIP-seq, cGMP/PKG assays, and xenograft sGC inhibition","pmids":["31405024","30718921"],"confidence":"Medium","gaps":["Single-lab mechanistic studies","Generalizability across fusion-positive tumor subtypes untested"]},{"year":2020,"claim":"Defined TMPRSS2 as the spike-priming protease enabling SARS-CoV-2 entry alongside ACE2, immediately establishing it as an antiviral target.","evidence":"Pseudovirus and authentic virus entry assays with camostat mesylate inhibition; plus enteroid infection showing TMPRSS2/TMPRSS4 fusogenic facilitation","pmids":["32142651","32404436"],"confidence":"High","gaps":["Cleavage sites and catalytic mechanism not yet structurally defined","Relative contribution of TMPRSS2 vs other proteases in vivo unresolved"]},{"year":2020,"claim":"Identified HAI-2 as the cognate endogenous inhibitor of TMPRSS2, linking protease regulation to substrate (pro-HGF) activation and prostate cancer metastasis.","evidence":"Co-IP/LC-MS/MS, recombinant inhibition assays, co-localization, pro-HGF/ECM degradation assays, and orthotopic xenograft metastasis model","pmids":["32778768"],"confidence":"High","gaps":["Physiological substrate repertoire beyond pro-HGF incompletely defined","Regulation of HAI-2/TMPRSS2 stoichiometry in tissue unknown"]},{"year":2020,"claim":"Established the degradation logic of the TMPRSS2-ERG oncoprotein, showing DNA-damage-induced GSK3β/WEE1 dual phosphorylation drives FBW7-mediated proteasomal turnover, a determinant of chemotherapy response.","evidence":"Phosphosite mutagenesis, kinase knockdown/inhibition, FBW7 co-IP, proteasome inhibition, and xenograft chemoresistance experiments","pmids":["32871104"],"confidence":"High","gaps":["Non-canonical degron recognition mechanism not structurally defined","Role of PTEN-loss escape in patients incomplete"]},{"year":2021,"claim":"Resolved that TMPRSS2 abundance dictates which entry pathway SARS-CoV-2 uses, showing the plasma-membrane and endosomal routes are mutually exclusive and kinetically distinct.","evidence":"Live-cell imaging of entry kinetics with reciprocal gain/loss of function and pathway-selective inhibitors","pmids":["34159616"],"confidence":"High","gaps":["Determinants of pathway choice in heterogeneous tissues unaddressed","Quantitative threshold of TMPRSS2 needed for plasma-membrane entry undefined"]},{"year":2021,"claim":"Connected TMPRSS2 to host restriction and innate immunity, showing TMPRSS2-routed plasma-membrane entry evades NCOA7 restriction and that α1-antitrypsin inactivates TMPRSS2 to block infection.","evidence":"NCOA7 over/knockout with furin-site mutagenesis; plus BAL protein-library screen, enzymatic inhibition, and primary airway viral replication assays","pmids":["34807954","33741941"],"confidence":"Medium","gaps":["Single-lab studies","In vivo relevance of α1AT/NCOA7 axis to disease severity unestablished"]},{"year":2022,"claim":"Provided the atomic structure and maturation mechanism of TMPRSS2, defining zymogen autocatalytic activation, S1/S2 cleavage, and the basis of inhibitor specificity.","evidence":"Recombinant protein, enzymatic assays, 1.95 Å co-crystal with nafamostat, and IC50 ranking of clinical inhibitors","pmids":["35676539"],"confidence":"High","gaps":["Structure of the full-length membrane-anchored protease not resolved","Conformational dynamics of activation captured only statically"]},{"year":2022,"claim":"Established TMPRSS2 dependence in vivo and variant-specific usage, showing knockout mice are protected across variants and that Omicron's reduced S1/S2 cleavage shifts it toward the cathepsin pathway in vitro yet retains in vivo TMPRSS2 dependence.","evidence":"TMPRSS2-KO mouse infection with Beta/Gamma/Omicron, viral titers, plus pseudovirus, spike cleavage, and syncytium assays","pmids":["36851486","36243815","35104837"],"confidence":"High","gaps":["Mechanism reconciling in vitro vs in vivo pathway preference incomplete","Cell types responsible for in vivo TMPRSS2 dependence not pinpointed"]},{"year":2022,"claim":"Dissected the furin/TMPRSS2 synergy and identified the S2' cleavage site, showing ACE2 engagement (via its collectrin domain) and TMPRSS2-mediated ACE2 shedding enhance fusion.","evidence":"Proteomics S2' site mapping, furin and TMPRSS2 inhibitors, ACE2 domain deletions, and quantitative cell-cell fusion assays","pmids":["35343766"],"confidence":"High","gaps":["Order and coupling of furin, TMPRSS2, and ACE2 events not fully sequenced","Single-lab system"]},{"year":2022,"claim":"Validated TMPRSS2 as a therapeutic target in vivo and expanded the inhibitor toolkit, including a low-nanomolar small molecule efficacious in mice and additional serpin, peptide, and peptidomimetic inhibitors.","evidence":"N-0385 efficacy in K18-hACE2 mice; plus antithrombin/heparin, lactoferricin, and catalytic-site peptidomimetic inhibition and viral infection assays","pmids":["35344983","36056630","36081512","35804152"],"confidence":"High","gaps":["Several inhibitor studies are single-lab in vitro","Clinical translation and resistance not addressed"]},{"year":2022,"claim":"Linked TMPRSS2 levels to host genetics and transcriptional/translational control, identifying a hypomorphic protective variant, an IL-1β–p38–GATA2 induction axis, and an mRNA G-quadruplex that represses translation.","evidence":"V160M functional pseudovirus assay with GenOMICC cohort association; cytokine/p38/GATA2 manipulation; RG4 biochemistry, translation reporters, and G4-stabilizer mouse infection","pmids":["35104687","34950146","35301316"],"confidence":"Medium","gaps":["Single-lab mechanistic studies","Causal contribution of each regulatory layer to clinical outcome uncertain"]},{"year":2023,"claim":"Revealed a non-protease function: TMPRSS2 acts as a direct proteinaceous receptor for HKU1, binding the viral RBD with high affinity independently of catalytic activity.","evidence":"Kd measurements, catalytically dead mutants, pseudovirus and authentic HKU1 infection of primary bronchial cells, and nanobody neutralization","pmids":["37879362"],"confidence":"High","gaps":["Whether receptor and protease roles operate on the same molecules simultaneously unclear","Relevance to other coronaviruses untested"]},{"year":2024,"claim":"Provided the structural basis for TMPRSS2 receptor function, showing HKU1 RBD engages the catalytic groove through an insertion subdomain, that sialoglycan-induced RBD opening synergizes with protein recognition, and that autocatalytic activation increases binding affinity.","evidence":"Cryo-EM and X-ray structures of HKU1 RBD/TMPRSS2 and nanobody/zymogen complexes with interface mutagenesis and species comparison","pmids":["38964329","38964326"],"confidence":"High","gaps":["Membrane-proximal architecture during fusion not resolved","Host-range determinants (residues 417/469) tested in limited species set"]},{"year":2022,"claim":"Extended TMPRSS2's receptor function beyond viruses, identifying it as a receptor for the bacterial toxin TcsH via genome-wide CRISPR screening.","evidence":"Two parallel CRISPR/Cas9 screens, TMPRSS2 deletion, CROPs-domain binding assays, and Tmprss2-/- mouse toxin challenge","pmids":["35882856"],"confidence":"High","gaps":["Whether catalytic activity contributes to toxin entry unknown","Structural basis of TcsH-TMPRSS2 binding undefined"]},{"year":2023,"claim":"Implicated TMPRSS2 in environmental carcinogenesis outside the prostate, showing PM2.5-activated AhR transcriptionally upregulates TMPRSS2 to promote lung cancer growth.","evidence":"AhR ChIP at the TMPRSS2 promoter, TMPRSS2 knockdown, anchorage-independent growth, and xenograft assays","pmids":["36975376"],"confidence":"Medium","gaps":["Single-lab study","Molecular role of TMPRSS2 protease activity in lung tumor growth undefined"]},{"year":null,"claim":"The endogenous physiological substrates and normal-tissue function of TMPRSS2 (beyond pro-HGF) remain undefined, as does how its protease and receptor roles are coordinated.","evidence":"No discovery in the timeline resolves the native, non-pathological substrate repertoire or in vivo physiological role","pmids":[],"confidence":"Low","gaps":["Native substrate set unknown","Physiological loss-of-function phenotype uncharacterized","Coupling of receptor vs protease functions unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[1,3,7,19]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,3,17]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[8,9,10]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[31,33,30]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,4]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[31,33]}],"pathway":[{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,2,8]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[3,17,19]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,21,31]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7,22,25]}],"complexes":["BAF (SWI/SNF) complex (via TMPRSS2-ERG)"],"partners":["ACE2","HAI-2","SERPINA1","ANTITHROMBIN","ERG","FBW7","FOXO1","BRD4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O15393","full_name":"Transmembrane protease serine 2","aliases":["Serine protease 10"],"length_aa":492,"mass_kda":53.9,"function":"Plasma membrane-anchored serine protease that cleaves at arginine residues (PubMed:32703818, PubMed:35676539, PubMed:37990007, PubMed:38964328). Participates in proteolytic cascades of relevance for the normal physiologic function of the prostate (PubMed:25122198). Androgen-induced TMPRSS2 activates several substrates that include pro-hepatocyte growth factor/HGF, the protease activated receptor-2/F2RL1 or matriptase/ST14 leading to extracellular matrix disruption and metastasis of prostate cancer cells (PubMed:15537383, PubMed:25122198, PubMed:26018085). In addition, activates trigeminal neurons and contribute to both spontaneous pain and mechanical allodynia (By similarity) (Microbial infection) Facilitates human coronaviruses SARS-CoV and SARS-CoV-2 infections via two independent mechanisms, proteolytic cleavage of ACE2 receptor which promotes viral uptake, and cleavage of coronavirus spike glycoproteins which activates the glycoprotein for host cell entry (PubMed:24227843, PubMed:32142651, PubMed:32404436, PubMed:33051876, PubMed:34159616, PubMed:35676539, PubMed:37990007). The cleavage of SARS-COV2 spike glycoprotein occurs between the S2 and S2' site (PubMed:32703818). Upon SARS-CoV-2 infection, increases syncytia formation by accelerating the fusion process (PubMed:33051876, PubMed:34159616, PubMed:35676539). Proteolytically cleaves and activates the spike glycoproteins of human coronavirus 229E (HCoV-229E) and human coronavirus EMC (HCoV-EMC) and the fusion glycoproteins F0 of Sendai virus (SeV), human metapneumovirus (HMPV), human parainfluenza 1, 2, 3, 4a and 4b viruses (HPIV). Essential for spread and pathogenesis of influenza A virus (strains H1N1, H3N2 and H7N9); involved in proteolytic cleavage and activation of hemagglutinin (HA) protein which is essential for viral infectivity (Microbial infection) Receptor for human coronavirus HKU1-CoV, acts synergistically with disialoside glycans to facilitate the entry of the virus. After binding to cell-surface disialoside glycans, the viral S protein interacts with the inactive form of TMPRSS2 and inhibits its protease activity","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/O15393/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TMPRSS2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TMPRSS2","total_profiled":1310},"omim":[{"mim_id":"611888","title":"ETS2 REPRESSOR FACTOR; ERF","url":"https://www.omim.org/entry/611888"},{"mim_id":"608067","title":"RING FINGER AND WD REPEAT DOMAINS-CONTAINING PROTEIN 2; RFWD2","url":"https://www.omim.org/entry/608067"},{"mim_id":"606565","title":"TRANSMEMBRANE PROTEASE, SERINE 4; TMPRSS4","url":"https://www.omim.org/entry/606565"},{"mim_id":"604503","title":"JUMONJI DOMAIN-CONTAINING PROTEIN 1C; JMJD1C","url":"https://www.omim.org/entry/604503"},{"mim_id":"602060","title":"TRANSMEMBRANE SERINE PROTEASE 2; TMPRSS2","url":"https://www.omim.org/entry/602060"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"prostate","ntpm":263.4},{"tissue":"stomach 1","ntpm":138.0}],"url":"https://www.proteinatlas.org/search/TMPRSS2"},"hgnc":{"alias_symbol":["PRSS10"],"prev_symbol":[]},"alphafold":{"accession":"O15393","domains":[{"cath_id":"3.10.250.10","chopping":"126-241","consensus_level":"high","plddt":91.6377,"start":126,"end":241},{"cath_id":"2.40.10.10","chopping":"248-492","consensus_level":"medium","plddt":88.5352,"start":248,"end":492}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O15393","model_url":"https://alphafold.ebi.ac.uk/files/AF-O15393-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O15393-F1-predicted_aligned_error_v6.png","plddt_mean":79.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TMPRSS2","jax_strain_url":"https://www.jax.org/strain/search?query=TMPRSS2"},"sequence":{"accession":"O15393","fasta_url":"https://rest.uniprot.org/uniprotkb/O15393.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O15393/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O15393"}},"corpus_meta":[{"pmid":"32142651","id":"PMC_32142651","title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.","date":"2020","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/32142651","citation_count":14365,"is_preprint":false},{"pmid":"16254181","id":"PMC_16254181","title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.","date":"2005","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/16254181","citation_count":3138,"is_preprint":false},{"pmid":"35104837","id":"PMC_35104837","title":"Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.","date":"2022","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/35104837","citation_count":851,"is_preprint":false},{"pmid":"32246845","id":"PMC_32246845","title":"SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells.","date":"2020","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/32246845","citation_count":821,"is_preprint":false},{"pmid":"32404436","id":"PMC_32404436","title":"TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes.","date":"2020","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32404436","citation_count":803,"is_preprint":false},{"pmid":"10485450","id":"PMC_10485450","title":"Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2.","date":"1999","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10485450","citation_count":427,"is_preprint":false},{"pmid":"32276929","id":"PMC_32276929","title":"TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?","date":"2020","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/32276929","citation_count":291,"is_preprint":false},{"pmid":"34159616","id":"PMC_34159616","title":"TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells.","date":"2021","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/34159616","citation_count":285,"is_preprint":false},{"pmid":"17334343","id":"PMC_17334343","title":"Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.","date":"2007","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/17334343","citation_count":229,"is_preprint":false},{"pmid":"28778717","id":"PMC_28778717","title":"TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections.","date":"2017","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/28778717","citation_count":213,"is_preprint":false},{"pmid":"33117379","id":"PMC_33117379","title":"ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33117379","citation_count":212,"is_preprint":false},{"pmid":"18172298","id":"PMC_18172298","title":"Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18172298","citation_count":211,"is_preprint":false},{"pmid":"32861070","id":"PMC_32861070","title":"ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19.","date":"2020","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/32861070","citation_count":187,"is_preprint":false},{"pmid":"33465165","id":"PMC_33465165","title":"Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2.","date":"2021","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/33465165","citation_count":178,"is_preprint":false},{"pmid":"35344983","id":"PMC_35344983","title":"A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic.","date":"2022","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/35344983","citation_count":177,"is_preprint":false},{"pmid":"29217279","id":"PMC_29217279","title":"Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry.","date":"2017","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/29217279","citation_count":173,"is_preprint":false},{"pmid":"35676539","id":"PMC_35676539","title":"Structure and activity of human TMPRSS2 protease implicated in SARS-CoV-2 activation.","date":"2022","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/35676539","citation_count":164,"is_preprint":false},{"pmid":"35343766","id":"PMC_35343766","title":"Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.","date":"2022","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/35343766","citation_count":144,"is_preprint":false},{"pmid":"11169526","id":"PMC_11169526","title":"Expression of transmembrane serine protease TMPRSS2 in mouse and human tissues.","date":"2001","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11169526","citation_count":135,"is_preprint":false},{"pmid":"20118910","id":"PMC_20118910","title":"Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort.","date":"2010","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/20118910","citation_count":130,"is_preprint":false},{"pmid":"29346775","id":"PMC_29346775","title":"BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29346775","citation_count":125,"is_preprint":false},{"pmid":"33290397","id":"PMC_33290397","title":"Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection.","date":"2020","source":"PLoS computational biology","url":"https://pubmed.ncbi.nlm.nih.gov/33290397","citation_count":117,"is_preprint":false},{"pmid":"33741941","id":"PMC_33741941","title":"Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33741941","citation_count":113,"is_preprint":false},{"pmid":"22245323","id":"PMC_22245323","title":"Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.","date":"2012","source":"The Journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/22245323","citation_count":105,"is_preprint":false},{"pmid":"33180746","id":"PMC_33180746","title":"Age-determined expression of priming protease TMPRSS2 and localization of SARS-CoV-2 in lung epithelium.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/33180746","citation_count":102,"is_preprint":false},{"pmid":"32861340","id":"PMC_32861340","title":"Targeting TMPRSS2 in SARS-CoV-2 Infection.","date":"2020","source":"Mayo Clinic proceedings","url":"https://pubmed.ncbi.nlm.nih.gov/32861340","citation_count":100,"is_preprint":false},{"pmid":"24505269","id":"PMC_24505269","title":"TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24505269","citation_count":100,"is_preprint":false},{"pmid":"37879362","id":"PMC_37879362","title":"TMPRSS2 is a functional receptor for human coronavirus HKU1.","date":"2023","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/37879362","citation_count":90,"is_preprint":false},{"pmid":"30078722","id":"PMC_30078722","title":"Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis.","date":"2018","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/30078722","citation_count":89,"is_preprint":false},{"pmid":"21040948","id":"PMC_21040948","title":"TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.","date":"2010","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21040948","citation_count":85,"is_preprint":false},{"pmid":"28849022","id":"PMC_28849022","title":"Significance of the TMPRSS2:ERG gene fusion in prostate cancer.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28849022","citation_count":85,"is_preprint":false},{"pmid":"33707363","id":"PMC_33707363","title":"Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.","date":"2021","source":"Journal of genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33707363","citation_count":84,"is_preprint":false},{"pmid":"36243815","id":"PMC_36243815","title":"Essential role of TMPRSS2 in SARS-CoV-2 infection in murine airways.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36243815","citation_count":84,"is_preprint":false},{"pmid":"32873700","id":"PMC_32873700","title":"Gene of the month: TMPRSS2 (transmembrane serine protease 2).","date":"2020","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32873700","citation_count":81,"is_preprint":false},{"pmid":"34045511","id":"PMC_34045511","title":"Androgen regulation of pulmonary AR, TMPRSS2 and ACE2 with implications for sex-discordant COVID-19 outcomes.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34045511","citation_count":80,"is_preprint":false},{"pmid":"32441816","id":"PMC_32441816","title":"Systematic analysis of ACE2 and TMPRSS2 expression in salivary glands reveals underlying transmission mechanism caused by SARS-CoV-2.","date":"2020","source":"Journal of medical virology","url":"https://pubmed.ncbi.nlm.nih.gov/32441816","citation_count":80,"is_preprint":false},{"pmid":"33278516","id":"PMC_33278516","title":"ACE2 and TMPRSS2 polymorphisms in various diseases with special reference to its impact on COVID-19 disease.","date":"2020","source":"Microbial pathogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/33278516","citation_count":76,"is_preprint":false},{"pmid":"32691890","id":"PMC_32691890","title":"ACE2, TMPRSS2, and Furin variants and SARS-CoV-2 infection in Madrid, Spain.","date":"2020","source":"Journal of medical virology","url":"https://pubmed.ncbi.nlm.nih.gov/32691890","citation_count":72,"is_preprint":false},{"pmid":"35301316","id":"PMC_35301316","title":"RNA G-quadruplex in TMPRSS2 reduces SARS-CoV-2 infection.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35301316","citation_count":68,"is_preprint":false},{"pmid":"36975376","id":"PMC_36975376","title":"PM2.5 promotes lung cancer progression through activation of the AhR-TMPRSS2-IL18 pathway.","date":"2023","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36975376","citation_count":65,"is_preprint":false},{"pmid":"32620366","id":"PMC_32620366","title":"COVID-19 and the male susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor.","date":"2020","source":"Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie","url":"https://pubmed.ncbi.nlm.nih.gov/32620366","citation_count":63,"is_preprint":false},{"pmid":"29844131","id":"PMC_29844131","title":"TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53-Mutated Prostate Cancer.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/29844131","citation_count":63,"is_preprint":false},{"pmid":"33029570","id":"PMC_33029570","title":"Molecular docking between human TMPRSS2 and SARS-CoV-2 spike protein: conformation and intermolecular interactions.","date":"2020","source":"AIMS microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/33029570","citation_count":60,"is_preprint":false},{"pmid":"35163273","id":"PMC_35163273","title":"The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35163273","citation_count":59,"is_preprint":false},{"pmid":"32703421","id":"PMC_32703421","title":"Genetic variants that influence SARS-CoV-2 receptor TMPRSS2 expression among population cohorts from multiple continents.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32703421","citation_count":58,"is_preprint":false},{"pmid":"28986382","id":"PMC_28986382","title":"Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion.","date":"2017","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28986382","citation_count":55,"is_preprint":false},{"pmid":"26774207","id":"PMC_26774207","title":"Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review.","date":"2015","source":"Clinical genitourinary cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26774207","citation_count":53,"is_preprint":false},{"pmid":"36851486","id":"PMC_36851486","title":"TMPRSS2 Is Essential for SARS-CoV-2 Beta and Omicron Infection.","date":"2023","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/36851486","citation_count":52,"is_preprint":false},{"pmid":"25263440","id":"PMC_25263440","title":"TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25263440","citation_count":52,"is_preprint":false},{"pmid":"33479506","id":"PMC_33479506","title":"High expression of ACE2 and TMPRSS2 and clinical characteristics of COVID-19 in colorectal cancer patients.","date":"2021","source":"NPJ precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33479506","citation_count":52,"is_preprint":false},{"pmid":"33296096","id":"PMC_33296096","title":"Expression of ACE2, TMPRSS2, and Furin in Mouse Ear Tissue, and the Implications for SARS-CoV-2 Infection.","date":"2020","source":"The Laryngoscope","url":"https://pubmed.ncbi.nlm.nih.gov/33296096","citation_count":49,"is_preprint":false},{"pmid":"32816230","id":"PMC_32816230","title":"ACE2 & TMPRSS2 Expressions in Head & Neck Tissues: A Systematic Review.","date":"2020","source":"Head and neck pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32816230","citation_count":48,"is_preprint":false},{"pmid":"33422505","id":"PMC_33422505","title":"Exposure to particulate matter upregulates ACE2 and TMPRSS2 expression in the murine lung.","date":"2021","source":"Environmental research","url":"https://pubmed.ncbi.nlm.nih.gov/33422505","citation_count":48,"is_preprint":false},{"pmid":"33958627","id":"PMC_33958627","title":"Association between ACE2 and TMPRSS2 nasopharyngeal expression and COVID-19 respiratory distress.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33958627","citation_count":43,"is_preprint":false},{"pmid":"35104687","id":"PMC_35104687","title":"A common TMPRSS2 variant has a protective effect against severe COVID-19.","date":"2022","source":"Current research in translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35104687","citation_count":43,"is_preprint":false},{"pmid":"32778768","id":"PMC_32778768","title":"Inhibition of TMPRSS2 by HAI-2 reduces prostate cancer cell invasion and metastasis.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32778768","citation_count":40,"is_preprint":false},{"pmid":"34001248","id":"PMC_34001248","title":"Initial study on TMPRSS2 p.Val160Met genetic variant in COVID-19 patients.","date":"2021","source":"Human genomics","url":"https://pubmed.ncbi.nlm.nih.gov/34001248","citation_count":40,"is_preprint":false},{"pmid":"32871104","id":"PMC_32871104","title":"DNA Damage Promotes TMPRSS2-ERG Oncoprotein Destruction and Prostate Cancer Suppression via Signaling Converged by GSK3β and WEE1.","date":"2020","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/32871104","citation_count":39,"is_preprint":false},{"pmid":"33706759","id":"PMC_33706759","title":"Upregulation of ACE2 and TMPRSS2 by particulate matter and idiopathic pulmonary fibrosis: a potential role in severe COVID-19.","date":"2021","source":"Particle and fibre toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/33706759","citation_count":39,"is_preprint":false},{"pmid":"38964328","id":"PMC_38964328","title":"Human coronavirus HKU1 recognition of the TMPRSS2 host receptor.","date":"2024","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/38964328","citation_count":38,"is_preprint":false},{"pmid":"31405024","id":"PMC_31405024","title":"Androgen Receptor-Activated Enhancers Simultaneously Regulate Oncogene TMPRSS2 and lncRNA PRCAT38 in Prostate Cancer.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31405024","citation_count":38,"is_preprint":false},{"pmid":"28055969","id":"PMC_28055969","title":"TMPRSS2-ERG fusion promotes prostate cancer metastases in bone.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28055969","citation_count":38,"is_preprint":false},{"pmid":"33245471","id":"PMC_33245471","title":"Expression and co-expression analyses of TMPRSS2, a key element in COVID-19.","date":"2020","source":"European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/33245471","citation_count":35,"is_preprint":false},{"pmid":"32940922","id":"PMC_32940922","title":"Expression of ACE2 and TMPRSS2 Proteins in the Upper and Lower Aerodigestive Tracts of Rats: Implications on COVID 19 Infections.","date":"2020","source":"The Laryngoscope","url":"https://pubmed.ncbi.nlm.nih.gov/32940922","citation_count":35,"is_preprint":false},{"pmid":"34807954","id":"PMC_34807954","title":"TMPRSS2 promotes SARS-CoV-2 evasion from NCOA7-mediated restriction.","date":"2021","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/34807954","citation_count":33,"is_preprint":false},{"pmid":"38964329","id":"PMC_38964329","title":"TMPRSS2 and glycan receptors synergistically facilitate coronavirus entry.","date":"2024","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/38964329","citation_count":32,"is_preprint":false},{"pmid":"30718921","id":"PMC_30718921","title":"TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30718921","citation_count":32,"is_preprint":false},{"pmid":"34590312","id":"PMC_34590312","title":"ACE2 and TMPRSS2 in human saliva can adsorb to the oral mucosal epithelium.","date":"2021","source":"Journal of anatomy","url":"https://pubmed.ncbi.nlm.nih.gov/34590312","citation_count":31,"is_preprint":false},{"pmid":"27041928","id":"PMC_27041928","title":"PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer.","date":"2016","source":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","url":"https://pubmed.ncbi.nlm.nih.gov/27041928","citation_count":30,"is_preprint":false},{"pmid":"33168188","id":"PMC_33168188","title":"Obesity alters Ace2 and Tmprss2 expression in lung, trachea, and esophagus in a sex-dependent manner: Implications for COVID-19.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/33168188","citation_count":29,"is_preprint":false},{"pmid":"33083800","id":"PMC_33083800","title":"Sex, androgens and regulation of pulmonary AR, TMPRSS2 and ACE2.","date":"2020","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/33083800","citation_count":27,"is_preprint":false},{"pmid":"34412632","id":"PMC_34412632","title":"Age and gender differences in ACE2 and TMPRSS2 expressions in oral epithelial cells.","date":"2021","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34412632","citation_count":27,"is_preprint":false},{"pmid":"33049583","id":"PMC_33049583","title":"GB-2 inhibits ACE2 and TMPRSS2 expression: In vivo and in vitro studies.","date":"2020","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/33049583","citation_count":26,"is_preprint":false},{"pmid":"34284028","id":"PMC_34284028","title":"Computational analysis of TMPRSS2 expression in normal and SARS-CoV-2-infected human tissues.","date":"2021","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/34284028","citation_count":26,"is_preprint":false},{"pmid":"35996506","id":"PMC_35996506","title":"ACE2 and TMPRSS2 SNPs as Determinants of Susceptibility to, and Severity of, a COVID-19 Infection.","date":"2022","source":"British journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/35996506","citation_count":26,"is_preprint":false},{"pmid":"36795725","id":"PMC_36795725","title":"TMPRSS2 polymorphism (rs12329760) and the severity of the COVID-19 in Iranian population.","date":"2023","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/36795725","citation_count":25,"is_preprint":false},{"pmid":"33638460","id":"PMC_33638460","title":"Spiking dependence of SARS-CoV-2 pathogenicity on TMPRSS2.","date":"2021","source":"Journal of medical virology","url":"https://pubmed.ncbi.nlm.nih.gov/33638460","citation_count":25,"is_preprint":false},{"pmid":"38964326","id":"PMC_38964326","title":"Structural basis of TMPRSS2 zymogen activation and recognition by the HKU1 seasonal coronavirus.","date":"2024","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/38964326","citation_count":24,"is_preprint":false},{"pmid":"35193695","id":"PMC_35193695","title":"Polymorphisms and mutations of ACE2 and TMPRSS2 genes are associated with COVID-19: a systematic review.","date":"2022","source":"European journal of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/35193695","citation_count":24,"is_preprint":false},{"pmid":"34950146","id":"PMC_34950146","title":"IL1β Promotes TMPRSS2 Expression and SARS-CoV-2 Cell Entry Through the p38 MAPK-GATA2 Axis.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34950146","citation_count":24,"is_preprint":false},{"pmid":"33380375","id":"PMC_33380375","title":"Phytopharmaceuticals mediated Furin and TMPRSS2 receptor blocking: can it be a potential therapeutic option for Covid-19?","date":"2020","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33380375","citation_count":23,"is_preprint":false},{"pmid":"32510524","id":"PMC_32510524","title":"Expression of ACE2, the SARS-CoV-2 receptor, and TMPRSS2 in prostate epithelial cells.","date":"2020","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/32510524","citation_count":23,"is_preprint":false},{"pmid":"21731703","id":"PMC_21731703","title":"Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21731703","citation_count":23,"is_preprint":false},{"pmid":"35072549","id":"PMC_35072549","title":"The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19.","date":"2022","source":"Expert opinion on drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35072549","citation_count":22,"is_preprint":false},{"pmid":"36056630","id":"PMC_36056630","title":"Native and activated antithrombin inhibits TMPRSS2 activity and SARS-CoV-2 infection.","date":"2022","source":"Journal of medical virology","url":"https://pubmed.ncbi.nlm.nih.gov/36056630","citation_count":20,"is_preprint":false},{"pmid":"29167279","id":"PMC_29167279","title":"Height, Obesity, and the Risk of TMPRSS2:ERG-Defined Prostate Cancer.","date":"2017","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29167279","citation_count":20,"is_preprint":false},{"pmid":"35000261","id":"PMC_35000261","title":"ACE2 and TMPRSS2 immunolocalization and oral manifestations of COVID-19.","date":"2022","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/35000261","citation_count":19,"is_preprint":false},{"pmid":"33421977","id":"PMC_33421977","title":"Genetic Susceptibility of ACE2 and TMPRSS2 in Six Common Cancers and Possible Impacts on COVID-19.","date":"2020","source":"Cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/33421977","citation_count":19,"is_preprint":false},{"pmid":"35804152","id":"PMC_35804152","title":"Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture.","date":"2022","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/35804152","citation_count":18,"is_preprint":false},{"pmid":"35103351","id":"PMC_35103351","title":"Estradiol reduces ACE2 and TMPRSS2 mRNA levels in A549 human lung epithelial cells.","date":"2022","source":"Drug development research","url":"https://pubmed.ncbi.nlm.nih.gov/35103351","citation_count":18,"is_preprint":false},{"pmid":"36088396","id":"PMC_36088396","title":"Profile of chimeric RNAs and TMPRSS2-ERG e2e4 isoform in neuroendocrine prostate cancer.","date":"2022","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/36088396","citation_count":17,"is_preprint":false},{"pmid":"37181497","id":"PMC_37181497","title":"PCA3 and TMPRSS2: ERG Urine Level as Diagnostic Biomarker of Prostate Cancer.","date":"2023","source":"Research and reports in urology","url":"https://pubmed.ncbi.nlm.nih.gov/37181497","citation_count":16,"is_preprint":false},{"pmid":"35882856","id":"PMC_35882856","title":"Paeniclostridium sordellii hemorrhagic toxin targets TMPRSS2 to induce colonic epithelial lesions.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35882856","citation_count":15,"is_preprint":false},{"pmid":"34913351","id":"PMC_34913351","title":"Interactions of renin-angiotensin system and COVID-19: the importance of daily rhythms in ACE2, ADAM17 and TMPRSS2 expression.","date":"2021","source":"Physiological research","url":"https://pubmed.ncbi.nlm.nih.gov/34913351","citation_count":15,"is_preprint":false},{"pmid":"27320318","id":"PMC_27320318","title":"TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27320318","citation_count":15,"is_preprint":false},{"pmid":"34399734","id":"PMC_34399734","title":"Gastrointestinal cancers, ACE-2/TMPRSS2 expression and susceptibility to COVID-19.","date":"2021","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/34399734","citation_count":14,"is_preprint":false},{"pmid":"36969980","id":"PMC_36969980","title":"Relevance of TMPRSS2, CD163/CD206, and CD33 in clinical severity stratification of COVID-19.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36969980","citation_count":14,"is_preprint":false},{"pmid":"28050800","id":"PMC_28050800","title":"Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.","date":"2017","source":"Hormones & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28050800","citation_count":14,"is_preprint":false},{"pmid":"36081512","id":"PMC_36081512","title":"Blockade of TMPRSS2-mediated priming of SARS-CoV-2 by lactoferricin.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36081512","citation_count":14,"is_preprint":false},{"pmid":"33301988","id":"PMC_33301988","title":"Covid-19 pathogenesis in prostatic cancer and TMPRSS2-ERG regulatory genetic pathway.","date":"2020","source":"Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/33301988","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49947,"output_tokens":9322,"usd":0.144836,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19625,"output_tokens":6505,"usd":0.130375,"stage2_stop_reason":"end_turn"},"total_usd":0.275211,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2020,\n      \"finding\": \"SARS-CoV-2 uses ACE2 as its entry receptor and TMPRSS2 for S protein priming; a clinically approved TMPRSS2 inhibitor (camostat mesylate) blocked viral entry into cells.\",\n      \"method\": \"Pseudovirus entry assay, authentic virus infection, pharmacological inhibition with camostat mesylate\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (pseudovirus, authentic virus, inhibitor blocking), widely replicated across many subsequent labs\",\n      \"pmids\": [\"32142651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"TMPRSS2 is a membrane-bound serine protease expressed on the cell surface; its expression in prostate epithelial cells is upregulated by androgens.\",\n      \"method\": \"cDNA microarray profiling, Northern analysis, in situ hybridization\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (microarray, Northern, ISH), foundational paper replicated by many subsequent studies\",\n      \"pmids\": [\"10485450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TMPRSS2 undergoes recurrent chromosomal rearrangements with ETS transcription factor genes ERG and ETV1 in prostate cancer; the androgen-responsive promoter elements of TMPRSS2 drive overexpression of the fusion ETS family members.\",\n      \"method\": \"Bioinformatics outlier expression analysis, FISH, RT-PCR, cell line experiments\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — FISH and RT-PCR in 29 tumor samples, cell line mechanistic experiments, widely replicated\",\n      \"pmids\": [\"16254181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Crystal structure of TMPRSS2 at 1.95 Å resolved in complex with the inhibitor nafamostat; TMPRSS2 is produced as a zymogen that undergoes autocatalytic maturation, cleaves SARS-CoV-2 spike protein at multiple sites including the S1/S2 site, and has a substrate-binding pocket with distinctive features that explain inhibitor specificity.\",\n      \"method\": \"Recombinant protein production, enzymatic activity assays, 1.95 Å X-ray co-crystal structure with nafamostat, IC50 measurements for clinical inhibitors\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure determination with functional validation (enzymatic assay, substrate cleavage, inhibitor ranking), single rigorous paper with multiple orthogonal methods\",\n      \"pmids\": [\"35676539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TMPRSS2 expression level determines the entry pathway of SARS-CoV-2: in TMPRSS2-expressing cells, virus enters rapidly (~10 min) at the plasma membrane in a pH-independent manner; in cells lacking TMPRSS2, virus is endocytosed and enters via acid-activated cathepsin L (~40–60 min post-infection). The two pathways are mutually exclusive.\",\n      \"method\": \"Live-cell imaging of viral entry kinetics, pharmacological inhibition of TMPRSS2 vs. cathepsin L, TMPRSS2 overexpression in non-expressing cells\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal gain/loss-of-function, live imaging, pharmacological pathway dissection; multiple orthogonal methods in one study\",\n      \"pmids\": [\"34159616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SARS-CoV-2 Omicron BA.1 spike is inefficiently cleaved at S1/S2 compared to Delta, and Omicron inefficiently uses TMPRSS2 for cell entry, shifting entry preference to the endocytic/cathepsin pathway; TMPRSS2 deletion affected Delta entry to a greater extent than Omicron, and syncytium formation by Omicron spike was substantially impaired consistent with defective TMPRSS2 usage.\",\n      \"method\": \"Pseudovirus entry assays, TMPRSS2 deletion experiments, drug inhibitor pathway studies, syncytium assays, spike cleavage analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (pseudovirus, authentic virus, TMPRSS2 KO, drug pathway inhibition, syncytium assay), published in Nature\",\n      \"pmids\": [\"35104837\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TMPRSS2 and TMPRSS4 facilitate SARS-CoV-2 spike fusogenic activity and promote viral entry into human small intestinal enterocytes; productive SARS-CoV-2 infection occurs in ACE2+ mature enterocytes in human small intestinal enteroids.\",\n      \"method\": \"Human small intestinal enteroid infection, spike fusogenicity assays, enterocyte infection experiments\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — primary human organoid model, spike fusogenicity assay, multiple tissue/cell-type validations in one study\",\n      \"pmids\": [\"32404436\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"α1-antitrypsin (α1AT) binds and inactivates the serine protease TMPRSS2, thereby inhibiting SARS-CoV-2 spike-mediated entry and viral replication in cell lines and primary human airway epithelial cultures at physiological concentrations.\",\n      \"method\": \"Bronchoalveolar lavage peptide/protein library screen, TMPRSS2 enzymatic activity assay, viral replication assay in primary cells, binding assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical binding/inhibition assay plus functional viral infection assay in primary cells, multiple cell types tested\",\n      \"pmids\": [\"33741941\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TMPRSS2 functions as a proteinaceous receptor for the seasonal human coronavirus HKU1; TMPRSS2 binds the HKU1 receptor-binding domain with high affinity (Kd 334 and 137 nM for HKU1A and HKU1B), triggers HKU1 spike-mediated cell-cell fusion and pseudovirus infection; catalytically inactive TMPRSS2 mutants retain receptor function but cannot cleave HKU1 spike. Anti-TMPRSS2 nanobodies block HKU1 infection of primary human bronchial cells.\",\n      \"method\": \"Pseudovirus infection assays, cell-cell fusion assays, binding affinity measurements, catalytically inactive TMPRSS2 mutants, anti-TMPRSS2 nanobodies, authentic HKU1 virus infection of primary cells\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (Kd measurement, mutagenesis, pseudovirus, authentic virus, primary cells, nanobody neutralization), published in Nature\",\n      \"pmids\": [\"37879362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cryo-EM structure of HKU1 RBD bound to human TMPRSS2 reveals that HKU1 RBD recognizes TMPRSS2 via an insertion subdomain through three distinct interfaces; sialoglycan binding induces a conformational change in the NTD that promotes RBD opening for TMPRSS2 recognition, demonstrating a synergistic glycan/protein receptor mechanism. Positions 417 and 469 in TMPRSS2 are determinants of HKU1 host tropism.\",\n      \"method\": \"Cryo-EM structure determination, mutagenesis, binding assays, pseudovirus infection assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structure combined with mutagenesis and functional binding/infection assays in one study\",\n      \"pmids\": [\"38964329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Crystal structure of HKU1-CoV RBD in complex with TMPRSS2 shows HKU1 recognizes residues lining the TMPRSS2 catalytic groove; structure of a receptor-blocking nanobody with zymogen and activated TMPRSS2 provides the structural basis of TMPRSS2 autocatalytic activating conformational change, which dramatically increases binding affinity for HKU1.\",\n      \"method\": \"X-ray crystal structure of HKU1 RBD/TMPRSS2 complex and nanobody/TMPRSS2 complexes, mutagenesis of interface residues, species comparison\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures of multiple complexes with mutagenesis validation, published in Cell\",\n      \"pmids\": [\"38964326\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TMPRSS2 is essential for SARS-CoV-2 Beta and Omicron infection in the murine airways; TMPRSS2 knockout mice showed strongly reduced replication of Beta variant in nose, trachea, and lung and were protected from weight loss and disease; Omicron infection was also significantly reduced in the upper and lower respiratory tract of TMPRSS2-KO mice despite Omicron preferring the cathepsin pathway in vitro.\",\n      \"method\": \"TMPRSS2-knockout mouse model, intranasal infection with Beta and Omicron variants, viral titer measurements in tissues, weight loss monitoring\",\n      \"journal\": \"Viruses\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO mouse model with defined in vivo phenotype, multiple variants tested, multiple tissue measurements\",\n      \"pmids\": [\"36851486\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Essential role of TMPRSS2 in SARS-CoV-2 infection of murine airways confirmed in vivo; Omicron replication is significantly reduced in TMPRSS2-knockout mice despite using the cathepsin pathway efficiently in vitro, demonstrating that in vivo TMPRSS2 dependency is not predicted by cell culture results alone.\",\n      \"method\": \"TMPRSS2-knockout mice, infection with multiple SARS-CoV-2 variants (Omicron, mouse-adapted QHmusX, Beta, Gamma), viral replication measurements in airways\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — TMPRSS2-KO mouse model, multiple viral strains, multiple tissue compartments, published in Nature Communications\",\n      \"pmids\": [\"36243815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TMPRSS2 rs12329760 T allele (p.Val160Met substitution) reduces TMPRSS2 catalytic activity and is less able to support SARS-CoV-2 spike-mediated entry in vitro; the T allele is associated with reduced likelihood of severe COVID-19 in a large clinical cohort.\",\n      \"method\": \"HEK293 cell co-transfection with ACE2 and WT or V160M TMPRSS2, SARS-CoV-2 pseudovirus entry assay, logistic regression in 2,244 ICU patients (GenOMICC study)\",\n      \"journal\": \"Current research in translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro functional assay showing reduced catalytic activity plus large clinical association study, single lab for the in vitro work\",\n      \"pmids\": [\"35104687\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TMPRSS2 promotes SARS-CoV-2 evasion from NCOA7-mediated restriction: overexpression of TMPRSS2, which routes virus to plasma membrane fusion rather than endosomal entry, renders SARS-CoV-2 less sensitive to NCOA7-mediated restriction; removal of the furin cleavage site similarly reduced NCOA7 sensitivity.\",\n      \"method\": \"TMPRSS2 overexpression, NCOA7 ectopic expression and gene knockout, spike pseudovirus infection, furin cleavage site mutagenesis\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function and loss-of-function with mechanistic mutagenesis, single lab\",\n      \"pmids\": [\"34807954\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Hydroxychloroquine blocks SARS-CoV-2 entry mediated by cathepsin L but not by TMPRSS2; SARS-CoV-2 entry is more dependent on TMPRSS2 than SARS-CoV-1 entry, a difference reversed by ablating the SARS-CoV-2 furin-cleavage site or introducing it into the SARS-CoV-1 spike.\",\n      \"method\": \"Pseudovirus entry assays with cathepsin vs. TMPRSS2 pathway inhibitors, spike furin-site mutagenesis, combination drug treatment experiments\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro reconstitution-like assay with mutagenesis demonstrating mechanistic basis, multiple orthogonal pharmacological and genetic approaches\",\n      \"pmids\": [\"33465165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Wild-type clinical isolates of human coronaviruses HCoV-OC43 and HCoV-HKU1 prefer cell-surface TMPRSS2 over endosomal cathepsins for cell entry in human airway epithelial cells; cell-culture-adapted HCoV-OC43 lost the ability to infect air-liquid interface cultures of human bronchial tracheal epithelial cells.\",\n      \"method\": \"Viral infection assays with cell-surface vs. endosomal pathway inhibitors, comparison of clinical isolates vs. cell-culture-adapted strains, air-liquid interface culture infection\",\n      \"journal\": \"Virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway dissection in physiologically relevant primary airway cultures, multiple coronavirus strains tested, single lab\",\n      \"pmids\": [\"29217279\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Furin and TMPRSS2 act synergistically in SARS-CoV-2 S protein processing and viral entry: furin primes S at S1/S2, and TMPRSS2-mediated ACE2 shedding is required for TMPRSS2-mediated enhancement of cell-to-cell fusion in the absence of S1/S2 priming; the collectrin dimerization domain of ACE2 is essential for the TMPRSS2 effect on fusion; the S2' cleavage site was identified as KPS815↓ and is strongly enhanced by ACE2 engagement.\",\n      \"method\": \"Proteomics identification of S2' cleavage site, pharmacological furin inhibitors (BOS), camostat (TMPRSS2 inhibitor), quantitative cell-to-cell fusion assays, ACE2 domain deletion experiments, SARS-CoV-2 infection of Calu-3 cells\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — proteomics-level cleavage site identification, mutagenesis/domain deletions, quantitative fusion assays, pharmacological combination treatment, multiple orthogonal approaches\",\n      \"pmids\": [\"35343766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The small-molecule TMPRSS2 inhibitor N-0385 exhibits low nanomolar potency against SARS-CoV-2 in human lung cells and colonoids; in K18-hACE2 transgenic mice, N-0385 provides high-level prophylactic and therapeutic benefit after multiple or single administrations, demonstrating that TTSP-mediated proteolytic maturation of spike is critical for SARS-CoV-2 infection in vivo.\",\n      \"method\": \"In vitro potency assays in Calu-3 and colonoids, K18-hACE2 transgenic mouse model, prophylactic and therapeutic dosing regimens, multiple variant testing\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo transgenic mouse model with prophylactic and therapeutic paradigms, multiple variants, multiple cell types in vitro, published in Nature\",\n      \"pmids\": [\"35344983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"HAI-2 (hepatocyte growth factor activator inhibitor-2) is a cognate inhibitor of TMPRSS2: HAI-2 binds TMPRSS2 with high affinity, co-localizes with TMPRSS2, inhibits TMPRSS2 proteolytic activity through both KD1 and KD2 domains, suppresses TMPRSS2-induced pro-HGF activation and extracellular matrix degradation, and blocks TMPRSS2-induced prostate cancer metastasis in orthotopic xenograft mice.\",\n      \"method\": \"Co-immunoprecipitation with LC/MS/MS identification, recombinant protein inhibitory assays, immunofluorescence co-localization, pro-HGF activation assay, invasion assay, orthotopic xenograft mouse model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP plus biochemical inhibition assay plus in vivo xenograft confirmation, multiple orthogonal methods in one study\",\n      \"pmids\": [\"32778768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"DNA damage induces proteasomal degradation of TMPRSS2-ERG oncoprotein through ERG Thr-187 and Tyr-190 phosphorylation by GSK3β and WEE1 kinases respectively; dual phosphorylation triggers recognition and ubiquitin-mediated degradation by the E3 ligase FBW7 independent of a canonical degron. PTEN deletion or GSK3β inactivation abolishes this degradation.\",\n      \"method\": \"Phosphorylation site mutagenesis, kinase knockdown/inhibition (GSK3β, WEE1), co-immunoprecipitation with FBW7, proteasome inhibitor experiments, in vitro cell culture and mouse xenograft chemotherapy resistance experiments\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — active-site mutagenesis, kinase identification, E3 ligase co-IP, in vivo xenograft validation, multiple orthogonal methods\",\n      \"pmids\": [\"32871104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"AR/FOXA1 binding to enhancers E1 and E2 on chromosome 21 mediates chromatin looping that co-regulates both TMPRSS2 and PRCAT38; acetyltransferase p300 activity mediates loop formation and enhancer activity; knockout of either enhancer simultaneously impaired transcription of both genes and inhibited cell growth and migration.\",\n      \"method\": \"ChIP-seq, chromatin conformation capture (looping assays), CRISPR enhancer knockout, qRT-PCR, cell proliferation and migration assays\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR enhancer KO, ChIP, looping assays; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"31405024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"IL-1β promotes TMPRSS2 expression and SARS-CoV-2 cell entry through the p38 MAPK–GATA2 signaling axis in lung epithelial cells.\",\n      \"method\": \"Cytokine treatment of cells, p38 MAPK inhibitors, GATA2 manipulation, TMPRSS2 expression measurement, pseudovirus/viral infection assays\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway dissection with pharmacological inhibitors and transcription factor manipulation, single lab\",\n      \"pmids\": [\"34950146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"An RNA G-quadruplex (RG4) structure within the TMPRSS2 mRNA inhibits TMPRSS2 translation; G4-stabilizing compounds attenuate SARS-CoV-2 infection in pseudovirus cell systems and mouse models; TMPRSS2 protein is increased in lungs of COVID-19 patients, consistent with loss of RG4-mediated translational repression.\",\n      \"method\": \"Bioinformatics RG4 prediction, biochemical/biophysical RG4 assays, translation reporter assays, G4 stabilizer treatment, pseudovirus infection, mouse infection model, COVID-19 patient lung protein analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical RG4 validation, functional translation assay, in vivo mouse model; single lab\",\n      \"pmids\": [\"35301316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PM2.5 activates AhR which translocates to the nucleus, binds the TMPRSS2 promoter, and upregulates TMPRSS2 and IL-18 expression to promote lung cancer progression; TMPRSS2 depletion in lung cancer cells suppressed anchorage-independent growth and xenograft tumor growth in mice.\",\n      \"method\": \"AhR nuclear translocation and ChIP at TMPRSS2 promoter, siRNA/shRNA TMPRSS2 knockdown, xenograft mouse model, anchorage-independent growth assay, PM2.5 long-term exposure cell model\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-based promoter binding, KO functional assay with in vivo xenograft, single lab\",\n      \"pmids\": [\"36975376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Antithrombin (AT) binds and inhibits TMPRSS2 as shown by molecular docking and enzyme activity assays; AT blocks entry of SARS-CoV, MERS-CoV, hCoV-229E, SARS-CoV-2 and Omicron spike-driven entry; activation of AT by heparin or fondaparinux increases its anti-TMPRSS2 activity.\",\n      \"method\": \"Molecular docking, TMPRSS2 enzymatic activity assays, spike pseudovirus entry assays, authentic SARS-CoV-2 lung cell infection, anticoagulant activation experiments\",\n      \"journal\": \"Journal of medical virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — enzymatic inhibition assay plus pseudovirus and authentic virus experiments, single lab\",\n      \"pmids\": [\"36056630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Lactoferricin and the N-terminal lactoferrin peptide pLF1 inhibit TMPRSS2 proteolytic activity, block SARS-CoV-2 spike protein processing, and inhibit SARS-CoV-2 infection of permissive cells.\",\n      \"method\": \"TMPRSS2 enzymatic activity assay, spike cleavage assay, SARS-CoV-2 pseudovirus and authentic virus infection assays\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — enzymatic inhibition plus viral infection functional assays, single lab\",\n      \"pmids\": [\"36081512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Peptidomimetic compounds designed to target the TMPRSS2 catalytic site inhibit TMPRSS2 serine protease activity, block SARS-CoV-2 spike pseudovirus entry, and inhibit authentic SARS-CoV-2 infection (including Delta and Omicron BA.1) with comparable efficacy to camostat mesylate; inhibitors are stable in blood serum/plasma.\",\n      \"method\": \"Molecular docking, TMPRSS2 enzymatic inhibition assays, SARS-CoV-2 pseudovirus entry assays, authentic SARS-CoV-2 infection assays, serum/plasma stability assays\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — structure-guided design with biochemical and multiple viral functional assays, single lab\",\n      \"pmids\": [\"35804152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TMPRSS2 is expressed in the epithelia of gastrointestinal, urogenital, and respiratory tracts in mice; in both mouse and human prostate, expression is localized to luminal epithelial cells. Mouse TMPRSS2 predicted protein shares 81.4% similarity with human TMPRSS2.\",\n      \"method\": \"Mouse TMPRSS2 cDNA cloning, Northern blot, in situ hybridization of mouse embryos and adult tissues, comparative expression analysis\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods (Northern, ISH, cDNA cloning) in mouse and human tissues, single lab\",\n      \"pmids\": [\"11169526\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TMPRSS2-ERG fusion product (but not wild-type ERG) negatively regulates PSMA expression at the transcriptional level; androgen stimulation increases TMPRSS2-ERG expression in VCaP cells, leading to decreased PSMA mRNA; ERG siRNA knockdown in VCaP cells enhances PSMA expression; TMPRSS2-ERG overexpression in LNCaP cells downregulates PSMA in a PSMA-luciferase reporter assay.\",\n      \"method\": \"siRNA knockdown of ERG, TMPRSS2-ERG overexpression in LNCaP cells, PSMA luciferase reporter assay, androgen treatment, flutamide (androgen antagonist) treatment\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with reporter assay, single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"21731703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TMPRSS2-ERG fusion protein directly and specifically regulates expression of the α1 and β1 subunits of soluble guanylyl cyclase (sGC), activating NO-cGMP-PKG signaling; ERG increases cGMP synthesis and PKG activity in prostate cancer cells; sGC inhibitor treatment represses tumor growth in TMPRSS2-ERG-positive PCa xenograft models and synergizes with enzalutamide.\",\n      \"method\": \"ChIP-seq, gene expression profiling, cGMP assay, PKG activity assay, sGC inhibitor treatment in xenograft models, ERG knockdown\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq, biochemical signaling assays, in vivo xenograft, single lab\",\n      \"pmids\": [\"30718921\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TMPRSS2-ERG fusion product mediates prostate oncogenesis by binding to BAF (mammalian SWI/SNF) ATP-dependent chromatin remodeling complexes; ERG drives genome-wide retargeting of BAF complexes in an ETS DNA-motif-dependent manner; ERG requires intact BAF complexes for chromatin occupancy and BAF ATPase activity for target gene regulation; in prostate organoids, BAF complexes are required for ERG-mediated basal-to-luminal transition.\",\n      \"method\": \"Co-immunoprecipitation, ChIP-seq for ERG and BAF subunits, BAF inhibition/depletion, prostate organoid model, gene expression profiling\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, genome-wide ChIP-seq, organoid functional model, ATPase activity requirement; multiple orthogonal methods, published in Molecular Cell\",\n      \"pmids\": [\"30078722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FOXO1 binds and inhibits the transcriptional activity of prostate cancer-associated ERG (including TMPRSS2-ERG fusion product) independently of FOXO1's own transcriptional activity; knockdown of endogenous FOXO1 increases invasion of TMPRSS2-ERG fusion-positive VCaP cells, an effect abolished by ERG knockdown; combined ERG transgene expression and Foxo1 deletion in mice results in high-grade prostatic intraepithelial neoplasia.\",\n      \"method\": \"Co-immunoprecipitation, ERG luciferase reporter assay, siRNA knockdown (FOXO1, ERG), invasion assay, transgenic/Foxo1-knockout mouse prostate model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, reporter assay, in vivo mouse epistasis model; multiple orthogonal methods, single lab\",\n      \"pmids\": [\"28986382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TMPRSS2-ERG fusion drives prostate cell proliferation and blocks differentiation to both neuroendocrine (NE) and luminal cell types; ERG represses AR-independent neuronal/NE genes and AR-regulated luminal genes; NE cells generated upon ERG knockdown/AR-inhibition are resistant to pharmacological AR inhibition and can revert to parental phenotype upon AR/ERG signaling restoration.\",\n      \"method\": \"ERG knockdown in TMPRSS2-ERG-positive cell line, ERG transgenic mouse model, transcriptional profiling, cell sorting, proliferation assays, androgen signaling inhibition\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockdown and transgenic mouse with transcriptional profiling and cell fate assays, single lab\",\n      \"pmids\": [\"25263440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BRD4 is essential for repair of DNA double-strand breaks and mediates formation of TMPRSS2-ERG gene rearrangements through the non-homologous end joining (NHEJ) pathway; genome-wide DNA breaks are associated with enhanced H4 acetylation leading to BRD4 recruitment and establishment of the DNA repair complex.\",\n      \"method\": \"BETi pharmacological inhibition, genome-wide DNA break mapping, ChIP for BRD4 and histone acetylation marks, NHEJ functional assays, clinical sample BRD4 protein analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, genome-wide DSB mapping, BETi functional experiments; single lab with multiple methods\",\n      \"pmids\": [\"29346775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TMPRSS2 is identified as a receptor for Paeniclostridium sordellii hemorrhagic toxin (TcsH) via genome-wide CRISPR/Cas9 screens; genetic deletion of TMPRSS2 confers cellular resistance to TcsH intoxication; TMPRSS2 and fucosylated glycans act as independent/redundant receptors both binding TcsH through its CROPs domain; Tmprss2-/- mice are protected from TcsH-induced systemic toxicity and colonic epithelial lesions.\",\n      \"method\": \"Genome-wide CRISPR/Cas9 screen (two parallel screens), TMPRSS2 genetic deletion, binding assays with CROPs domain, Tmprss2-/- mouse model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide CRISPR screen validated by KO, domain binding assay, in vivo KO mouse model, published in Nature Communications\",\n      \"pmids\": [\"35882856\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TMPRSS2 is a type II transmembrane serine protease that undergoes autocatalytic zymogen activation; it primes the spike proteins of SARS-CoV-2 (at S1/S2 and S2' sites), other coronaviruses (including SARS-CoV, MERS-CoV, HCoV-229E, OC43, and HKU1), and influenza viruses by proteolytic cleavage, enabling virus-host membrane fusion at the plasma membrane surface (bypassing the endosomal cathepsin pathway); for HKU1, TMPRSS2 additionally serves as a direct proteinaceous receptor recognized by the RBD; in the prostate, TMPRSS2 expression is androgen-regulated via AR/FOXA1-driven enhancers, and its promoter region drives recurrent fusion with ETS oncogenes (most commonly ERG) in ~50% of prostate cancers, with the fusion product activating BAF chromatin remodeling, NO-cGMP signaling, and blocking neuroendocrine/luminal differentiation; its cognate endogenous inhibitor is HAI-2, and it is also inhibited by circulating serpins α1-antitrypsin and antithrombin; TMPRSS2-ERG oncoprotein is degraded by the proteasome following GSK3β/WEE1-mediated dual phosphorylation and FBW7 recognition.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TMPRSS2 is an androgen-regulated, cell-surface type II transmembrane serine protease that is produced as a zymogen and undergoes autocatalytic maturation, with its substrate-binding pocket explaining the specificity of clinical inhibitors [#1, #3]. Its best-characterized role is in respiratory and enteric virus entry: TMPRSS2 primes the spike protein of SARS-CoV-2 by cleaving at the S1/S2 and S2' (KPS815\\u2193) sites, enabling rapid, pH-independent fusion at the plasma membrane and bypassing the slower endosomal cathepsin L pathway, with the two entry routes being mutually exclusive [#0, #4, #17]. This priming function extends across coronaviruses (HCoV-OC43, HKU1) and is required in vivo, as TMPRSS2-knockout mice show strongly reduced replication of multiple SARS-CoV-2 variants even when those variants favor the cathepsin pathway in culture [#11, #12, #16, #18]. For HKU1, TMPRSS2 additionally serves as a direct proteinaceous receptor: the HKU1 receptor-binding domain engages the TMPRSS2 catalytic groove through an insertion subdomain, sialoglycan binding promotes RBD opening, and autocatalytic activation increases receptor affinity, while catalytically dead TMPRSS2 still functions as a receptor [#8, #9, #10]. TMPRSS2 is inhibited by the cognate inhibitor HAI-2 and by circulating serpins \\u03b11-antitrypsin and antithrombin, all of which block its proteolytic activity and viral entry [#7, #19, #25]. Independently, the androgen-responsive TMPRSS2 promoter drives recurrent fusion with ETS oncogenes (ERG, ETV1) in prostate cancer; the TMPRSS2-ERG oncoprotein retargets BAF (SWI/SNF) chromatin-remodeling complexes, activates NO-cGMP-PKG signaling, blocks neuroendocrine and luminal differentiation, and is destabilized by GSK3\\u03b2/WEE1-driven dual phosphorylation and FBW7-mediated proteasomal degradation [#2, #20, #31, #30, #33]. TMPRSS2 is also a receptor for Paeniclostridium sordellii hemorrhagic toxin TcsH [#35].\"  ,\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established TMPRSS2 as a cell-surface serine protease whose expression is androgen-driven in prostate epithelium, defining the regulatory wiring later exploited by oncogenic fusions.\",\n      \"evidence\": \"cDNA microarray, Northern blot, and in situ hybridization in prostate epithelial cells\",\n      \"pmids\": [\"10485450\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify physiological substrates\", \"No mechanism for how androgen signaling reaches the gene\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Mapped TMPRSS2 tissue distribution to GI, urogenital, and respiratory epithelia and to prostate luminal cells, establishing the anatomical contexts relevant to both cancer and later viral entry roles.\",\n      \"evidence\": \"cDNA cloning, Northern blot, in situ hybridization in mouse and human tissues\",\n      \"pmids\": [\"11169526\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of broad epithelial expression unaddressed\", \"No protease activity data\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showed that the androgen-responsive TMPRSS2 promoter fuses to ETS oncogenes (ERG, ETV1) to drive their overexpression, defining the founding oncogenic mechanism of TMPRSS2 in prostate cancer.\",\n      \"evidence\": \"Outlier expression bioinformatics, FISH, RT-PCR, and cell line experiments in prostate tumors\",\n      \"pmids\": [\"16254181\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish downstream effector pathways of the fusion oncoprotein\", \"Mechanism of rearrangement formation unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrated that clinical coronavirus isolates prefer cell-surface TMPRSS2 over endosomal cathepsins, foreshadowing TMPRSS2 as a general coronavirus entry factor.\",\n      \"evidence\": \"Pathway-inhibitor infection assays comparing clinical vs. culture-adapted strains in human airway cultures\",\n      \"pmids\": [\"29217279\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct cleavage of spike not biochemically resolved here\", \"Single-lab pharmacological dissection\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Resolved how the TMPRSS2-ERG oncoprotein reprograms chromatin and cell fate, showing it retargets BAF complexes and blocks differentiation, explaining its oncogenic output.\",\n      \"evidence\": \"Co-IP, ERG/BAF ChIP-seq, BAF depletion, and prostate organoid basal-to-luminal transition assays; plus ERG-driven repression of NE/luminal programs\",\n      \"pmids\": [\"30078722\", \"25263440\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How fusion alters BAF assembly stoichiometry unresolved\", \"Relationship between chromatin retargeting and clinical progression incomplete\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified the AR/FOXA1-driven enhancers and downstream NO-cGMP-PKG signaling axis activated by TMPRSS2-ERG, linking enhancer biology to a druggable oncogenic effector pathway.\",\n      \"evidence\": \"ChIP-seq, chromatin looping, CRISPR enhancer knockout; sGC subunit ChIP-seq, cGMP/PKG assays, and xenograft sGC inhibition\",\n      \"pmids\": [\"31405024\", \"30718921\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab mechanistic studies\", \"Generalizability across fusion-positive tumor subtypes untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined TMPRSS2 as the spike-priming protease enabling SARS-CoV-2 entry alongside ACE2, immediately establishing it as an antiviral target.\",\n      \"evidence\": \"Pseudovirus and authentic virus entry assays with camostat mesylate inhibition; plus enteroid infection showing TMPRSS2/TMPRSS4 fusogenic facilitation\",\n      \"pmids\": [\"32142651\", \"32404436\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cleavage sites and catalytic mechanism not yet structurally defined\", \"Relative contribution of TMPRSS2 vs other proteases in vivo unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified HAI-2 as the cognate endogenous inhibitor of TMPRSS2, linking protease regulation to substrate (pro-HGF) activation and prostate cancer metastasis.\",\n      \"evidence\": \"Co-IP/LC-MS/MS, recombinant inhibition assays, co-localization, pro-HGF/ECM degradation assays, and orthotopic xenograft metastasis model\",\n      \"pmids\": [\"32778768\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological substrate repertoire beyond pro-HGF incompletely defined\", \"Regulation of HAI-2/TMPRSS2 stoichiometry in tissue unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established the degradation logic of the TMPRSS2-ERG oncoprotein, showing DNA-damage-induced GSK3\\u03b2/WEE1 dual phosphorylation drives FBW7-mediated proteasomal turnover, a determinant of chemotherapy response.\",\n      \"evidence\": \"Phosphosite mutagenesis, kinase knockdown/inhibition, FBW7 co-IP, proteasome inhibition, and xenograft chemoresistance experiments\",\n      \"pmids\": [\"32871104\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Non-canonical degron recognition mechanism not structurally defined\", \"Role of PTEN-loss escape in patients incomplete\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Resolved that TMPRSS2 abundance dictates which entry pathway SARS-CoV-2 uses, showing the plasma-membrane and endosomal routes are mutually exclusive and kinetically distinct.\",\n      \"evidence\": \"Live-cell imaging of entry kinetics with reciprocal gain/loss of function and pathway-selective inhibitors\",\n      \"pmids\": [\"34159616\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of pathway choice in heterogeneous tissues unaddressed\", \"Quantitative threshold of TMPRSS2 needed for plasma-membrane entry undefined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Connected TMPRSS2 to host restriction and innate immunity, showing TMPRSS2-routed plasma-membrane entry evades NCOA7 restriction and that \\u03b11-antitrypsin inactivates TMPRSS2 to block infection.\",\n      \"evidence\": \"NCOA7 over/knockout with furin-site mutagenesis; plus BAL protein-library screen, enzymatic inhibition, and primary airway viral replication assays\",\n      \"pmids\": [\"34807954\", \"33741941\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab studies\", \"In vivo relevance of \\u03b11AT/NCOA7 axis to disease severity unestablished\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Provided the atomic structure and maturation mechanism of TMPRSS2, defining zymogen autocatalytic activation, S1/S2 cleavage, and the basis of inhibitor specificity.\",\n      \"evidence\": \"Recombinant protein, enzymatic assays, 1.95 \\u00c5 co-crystal with nafamostat, and IC50 ranking of clinical inhibitors\",\n      \"pmids\": [\"35676539\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of the full-length membrane-anchored protease not resolved\", \"Conformational dynamics of activation captured only statically\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established TMPRSS2 dependence in vivo and variant-specific usage, showing knockout mice are protected across variants and that Omicron's reduced S1/S2 cleavage shifts it toward the cathepsin pathway in vitro yet retains in vivo TMPRSS2 dependence.\",\n      \"evidence\": \"TMPRSS2-KO mouse infection with Beta/Gamma/Omicron, viral titers, plus pseudovirus, spike cleavage, and syncytium assays\",\n      \"pmids\": [\"36851486\", \"36243815\", \"35104837\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism reconciling in vitro vs in vivo pathway preference incomplete\", \"Cell types responsible for in vivo TMPRSS2 dependence not pinpointed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Dissected the furin/TMPRSS2 synergy and identified the S2' cleavage site, showing ACE2 engagement (via its collectrin domain) and TMPRSS2-mediated ACE2 shedding enhance fusion.\",\n      \"evidence\": \"Proteomics S2' site mapping, furin and TMPRSS2 inhibitors, ACE2 domain deletions, and quantitative cell-cell fusion assays\",\n      \"pmids\": [\"35343766\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Order and coupling of furin, TMPRSS2, and ACE2 events not fully sequenced\", \"Single-lab system\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Validated TMPRSS2 as a therapeutic target in vivo and expanded the inhibitor toolkit, including a low-nanomolar small molecule efficacious in mice and additional serpin, peptide, and peptidomimetic inhibitors.\",\n      \"evidence\": \"N-0385 efficacy in K18-hACE2 mice; plus antithrombin/heparin, lactoferricin, and catalytic-site peptidomimetic inhibition and viral infection assays\",\n      \"pmids\": [\"35344983\", \"36056630\", \"36081512\", \"35804152\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Several inhibitor studies are single-lab in vitro\", \"Clinical translation and resistance not addressed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linked TMPRSS2 levels to host genetics and transcriptional/translational control, identifying a hypomorphic protective variant, an IL-1\\u03b2\\u2013p38\\u2013GATA2 induction axis, and an mRNA G-quadruplex that represses translation.\",\n      \"evidence\": \"V160M functional pseudovirus assay with GenOMICC cohort association; cytokine/p38/GATA2 manipulation; RG4 biochemistry, translation reporters, and G4-stabilizer mouse infection\",\n      \"pmids\": [\"35104687\", \"34950146\", \"35301316\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab mechanistic studies\", \"Causal contribution of each regulatory layer to clinical outcome uncertain\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Revealed a non-protease function: TMPRSS2 acts as a direct proteinaceous receptor for HKU1, binding the viral RBD with high affinity independently of catalytic activity.\",\n      \"evidence\": \"Kd measurements, catalytically dead mutants, pseudovirus and authentic HKU1 infection of primary bronchial cells, and nanobody neutralization\",\n      \"pmids\": [\"37879362\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether receptor and protease roles operate on the same molecules simultaneously unclear\", \"Relevance to other coronaviruses untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Provided the structural basis for TMPRSS2 receptor function, showing HKU1 RBD engages the catalytic groove through an insertion subdomain, that sialoglycan-induced RBD opening synergizes with protein recognition, and that autocatalytic activation increases binding affinity.\",\n      \"evidence\": \"Cryo-EM and X-ray structures of HKU1 RBD/TMPRSS2 and nanobody/zymogen complexes with interface mutagenesis and species comparison\",\n      \"pmids\": [\"38964329\", \"38964326\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Membrane-proximal architecture during fusion not resolved\", \"Host-range determinants (residues 417/469) tested in limited species set\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended TMPRSS2's receptor function beyond viruses, identifying it as a receptor for the bacterial toxin TcsH via genome-wide CRISPR screening.\",\n      \"evidence\": \"Two parallel CRISPR/Cas9 screens, TMPRSS2 deletion, CROPs-domain binding assays, and Tmprss2-/- mouse toxin challenge\",\n      \"pmids\": [\"35882856\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether catalytic activity contributes to toxin entry unknown\", \"Structural basis of TcsH-TMPRSS2 binding undefined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Implicated TMPRSS2 in environmental carcinogenesis outside the prostate, showing PM2.5-activated AhR transcriptionally upregulates TMPRSS2 to promote lung cancer growth.\",\n      \"evidence\": \"AhR ChIP at the TMPRSS2 promoter, TMPRSS2 knockdown, anchorage-independent growth, and xenograft assays\",\n      \"pmids\": [\"36975376\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab study\", \"Molecular role of TMPRSS2 protease activity in lung tumor growth undefined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The endogenous physiological substrates and normal-tissue function of TMPRSS2 (beyond pro-HGF) remain undefined, as does how its protease and receptor roles are coordinated.\",\n      \"evidence\": \"No discovery in the timeline resolves the native, non-pathological substrate repertoire or in vivo physiological role\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Native substrate set unknown\", \"Physiological loss-of-function phenotype uncharacterized\", \"Coupling of receptor vs protease functions unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [1, 3, 7, 19]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 3, 17]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [8, 9, 10]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [31, 33, 30]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 4]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [31, 33]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 2, 8]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [3, 17, 19]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 21, 31]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 22, 25]}\n    ],\n    \"complexes\": [\"BAF (SWI/SNF) complex (via TMPRSS2-ERG)\"],\n    \"partners\": [\"ACE2\", \"HAI-2\", \"SERPINA1\", \"antithrombin\", \"ERG\", \"FBW7\", \"FOXO1\", \"BRD4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}